Characteristics of, and risk factors for, infections in patients with cancer treated with dasatinib and a brief review of other complications

Management of Drug Toxicities in Chronic Myeloid Leukaemia

(2009) Michael J. Mauro et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

(2009) Hagop Kantarjian et al.   CANCER

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

(2008) Hugues de Lavallade et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dasatinib inhibits the proliferation and function of CD4+CD25+regulatory T cells

(2008) Fei Fei et al.   BRITISH JOURNAL OF HAEMATOLOGY

Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens

(2008) Fei Fei et al.   EXPERIMENTAL HEMATOLOGY

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

(2008) A Hochhaus et al.   LEUKEMIA

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase

(2008) J Cortes et al.   LEUKEMIA